Brain and Central Nervous System Tumors
Conditions
Keywords
adult glioblastoma, adult giant cell glioblastoma, adult gliosarcoma, adult anaplastic astrocytoma, adult anaplastic ependymoma, adult anaplastic oligodendroglioma, adult mixed glioma
Brief summary
RATIONALE: Diagnostic procedures, such as MRI, may help in learning how well radiation therapy and chemotherapy work in killing tumor cells and allow doctors to plan better treatment. PURPOSE: This clinical trial is studying MRI scans to see how well they evaluate the effects of radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma multiforme or anaplastic glioma.
Detailed description
OBJECTIVES: Primary * To quantitatively compare the relative cerebral blood volume/flow, mean transit time, and mean vessel diameter as measured by perfusion-weighted MRI before, during, and after chemoradiotherapy in patients with newly diagnosed glioblastoma multiforme. * To measure the permeability-surface area product on a voxel-by-voxel basis before, during, and after chemoradiotherapy in these patients. * To measure the full water self-diffusion tensor on a voxel-by-voxel basis before, during, and after chemoradiotherapy in these patients. * To compare the tensor fractional anisotropy before, during, and after chemoradiotherapy in these patients. * To compare the relative regional concentrations of choline, N-acetyl-asparate, and myoinositol as measured by magnetic resonance spectroscopy before, during, and after chemoradiotherapy to interrogate cell membrane turnover, neuronal integrity, and glial reactions. * To test the affects of a short period of 100% oxygen inhalation on imaging of tumor and surrounding tissue regions of interest, specifically cerebral blood volume changes in each area as compared to room air. Secondary * To collect blood and urine samples for correlation analysis between imaging changes, molecular markers (including genetic markers), and clinical outcome of glioblastoma multiforme (phenotypic information). * To correlate blood and urine biomarkers and blood genetic markers with tumor expression of these markers. OUTLINE: Patients undergo radiotherapy once daily 5 days a week for 6 weeks. Patients also receive oral temozolomide once daily 7 days a week during radiotherapy. After completion of chemoradiotherapy, patients receive oral temozolomide once daily for 5 days. Treatment with temozolomide repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, including perfusion- and diffusion-weighted MRI, diffusion tensor imaging, and magnetic resonance spectroscopy prior to initiation of chemoradiotherapy, once weekly during chemoradiotherapy, and then monthly until tumor progression or until completion of 6 courses of post chemoradiotherapy. After completion of study treatment, patients are followed annually.
Interventions
DRUGtemozolomide
Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
MRI
RADIATIONPhoton Radiation Therapy
Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
Sponsors
National Cancer Institute (NCI)
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Newly diagnosed anaplastic glioma (WHO grade III) or glioblastoma multiforme (WHO grade IV) * Measurable disease * Residual tumor size after surgery ≥ 1 cm in one dimension * Planning to undergo standard chemoradiotherapy with temozolomide PATIENT CHARACTERISTICS: * Glomerular filtration rate ≥ 60 mL/min * Mini Mental Status Exam score \> 15 * Sufficiently competent to give informed consent * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for 2 months after completion of study treatment * No contraindication to MRI or to use of the contrast agent gadolinium, including any of the following: * Claustrophobia * Metallic objects or implanted medical devices (e.g., cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants) * Sickle cell disease * Renal failure * High risk for kidney disease (e.g., age \> 60 years, diabetes, or history of systemic lupus erythematosus or multiple myeloma) * No known history of chronic obstructive pulmonary disease or emphysema * No other co-existing condition that, in the judgement of the investigator, may increase risk to the patient PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Non-VEGF investigational agent allowed * No concurrent chemotherapy (other than temozolomide) * No concurrent electron, proton, particle, or implant radiotherapy * No concurrent stereotactic radiosurgery * No concurrent anti-VEGF anti-tumor agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | Relative cerebral blood volume (rCBV) is the blood volume in the region of interest (ROI) divided by the blood volume in the symmetrical region on the other side of the normal brain (control region). CBV was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide |
| Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | Relative cerebral blood flow (rCBF) is the blood flow rate (the volume of blood passing through the specified are over a specified period of time) in the region of interest (ROI) divided by the blood flow rate in the symmetrical region on the other side of the normal brain (control region). CBF was assessed using spin-echo post-contrast T1-weighted images. CBF was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide |
| Vessel Diameter as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | — |
| Mean Transit Time as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | Mean transit time (MTT) corresponds to the average time, in seconds, that red blood cells spend within a determinate volume of capillary circulation. |
| Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | Permeability-surface Area Product (Ktrans). Ktrans reflects the efflux rate of contrast from blood plasma into the tissue extravascular extracellular space (EES). Ktrans was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide |
| Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue. ADC was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide |
| Tensor Fractional Anisotropy Before, During, and After Chemoradiotherapy | Baseline, weekly during treatment, monthly following treatment for up to six months | Fractional anisotropy (FA) is a measure of the directionality of the molecular motion of water. |
| Relative Regional Concentrations of Choline, N-acetyl-asparate, and Myoinositol as Measured by Magnetic Resonance Spectroscopy Before, During, and After Chemoradiotherapy to Interrogate Cell Membrane Turnover, Neuronal Integrity, and Glial Reactions | Baseline, weekly during treatment, monthly following treatment for up to six months | — |
| Affects of a Short Period of 100% Oxygen Inhalation on Imaging of Tumor and Surrounding Tissue Regions of Interest, Specifically Cerebral Blood Volume Changes in Each Area as Compared to Room Air | Baseline, weekly during treatment, monthly following treatment for up to six months | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Temozolomide and Radiation Therapy temozolomide: Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
Imaging biomarker analysis: MRI
Photon Radiation Therapy: Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions. | 14 |
| Total | 14 |
Baseline characteristics
| Characteristic | Temozolomide and Radiation Therapy |
|---|---|
| Age, Continuous | 60 years |
| Karnofsky Performance Status | 90 units on a scale |
| Region of Enrollment United States | 14 participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Affects of a Short Period of 100% Oxygen Inhalation on Imaging of Tumor and Surrounding Tissue Regions of Interest, Specifically Cerebral Blood Volume Changes in Each Area as Compared to Room Air
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: Data not collected
Primary
Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy
Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue. ADC was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: One participant withdrew consent after baseline and was excluded from the analysis set. The number of patients evaluated decreased over time due to participants experiencing disease progression and discontinuing from the study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Baseline 1 | 0.00110 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Baseline 2 | 0.00113 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Week 1 CRT | 0.00106 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Week 2 CRT | 0.00110 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Week 3 CRT | 0.00118 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Week 4 CRT | 0.00122 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Pre-C4 TMZ | 0.00133 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Pre-C5 TMZ | 0.00148 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Pre-C6 TMZ | 0.00179 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Post-TMZ | 0.00140 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Week 5 CRT | 0.00125 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Week 6 CRT | 0.00125 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Pre-C1 TMZ | 0.00132 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Pre-C2 TMZ | 0.00127 mm2/s |
| Temozolomide and Radiation Therapy | Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy | Pre-C3 TMZ | 0.00108 mm2/s |
Primary
Mean Transit Time as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy
Mean transit time (MTT) corresponds to the average time, in seconds, that red blood cells spend within a determinate volume of capillary circulation.
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: Data not collected
Primary
Permeability-surface Area Product Before, During, and After Chemoradiotherapy
Permeability-surface Area Product (Ktrans). Ktrans reflects the efflux rate of contrast from blood plasma into the tissue extravascular extracellular space (EES). Ktrans was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: One participant withdrew consent after baseline and was excluded from the analysis set. The number of patients evaluated decreased over time due to participants experiencing disease progression and discontinuing from the study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Baseline 1 | 0.053 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Baseline 2 | 0.039 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Week 1 CRT | 0.055 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Week 2 CRT | 0.048 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Week 3 CRT | 0.055 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Week 4 CRT | 0.053 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Week 5 CRT | 0.058 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Week 6 CRT | 0.059 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Pre-C1 TMZ | 0.063 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Pre-C2 TMZ | 0.042 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Pre-C3 TMZ | 0.050 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Pre-C4 TMZ | 0.058 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Pre-C5 TMZ | 0.056 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Pre-C6 TMZ | 0.060 min ^-1 |
| Temozolomide and Radiation Therapy | Permeability-surface Area Product Before, During, and After Chemoradiotherapy | Post-TMZ | 0.032 min ^-1 |
Primary
Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy
Relative cerebral blood flow (rCBF) is the blood flow rate (the volume of blood passing through the specified are over a specified period of time) in the region of interest (ROI) divided by the blood flow rate in the symmetrical region on the other side of the normal brain (control region). CBF was assessed using spin-echo post-contrast T1-weighted images. CBF was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: One participant withdrew consent after baseline and was excluded from the analysis set. The number of patients evaluated decreased over time due to participants experiencing disease progression and discontinuing from the study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline 2 | 0.86 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 1 CRT | 0.92 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 3 CRT | 0.80 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 4 CRT | 0.79 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 5 CRT | 0.83 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C1 TMZ | 0.63 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C2 TMZ | 0.59 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C3 TMZ | 0.60 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C4 TMZ | 0.60 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C5 TMZ | 0.52 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C6 TMZ | 0.47 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Post-TMZ | 0.37 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline 1 | 0.83 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 2 CRT | 0.94 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 6 CRT | 0.73 ratio |
Primary
Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy
Relative cerebral blood volume (rCBV) is the blood volume in the region of interest (ROI) divided by the blood volume in the symmetrical region on the other side of the normal brain (control region). CBV was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation. CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: One participant withdrew consent after baseline and was excluded from the analysis set. The number of patients evaluated decreased over time due to participants experiencing disease progression and discontinuing from the study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline 2 | 0.90 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 1 CRT | 0.95 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 4 CRT | 0.83 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C2 TMZ | 0.61 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C3 TMZ | 0.59 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C4 TMZ | 0.65 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C5 TMZ | 0.61 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C6 TMZ | 0.64 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Post-TMZ | 0.32 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Baseline 1 | 0.88 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 2 CRT | 1.0 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 3 CRT | 0.88 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 5 CRT | 0.86 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Week 6 CRT | 0.76 ratio |
| Temozolomide and Radiation Therapy | Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy | Pre-C1 TMZ | 0.68 ratio |
Primary
Relative Regional Concentrations of Choline, N-acetyl-asparate, and Myoinositol as Measured by Magnetic Resonance Spectroscopy Before, During, and After Chemoradiotherapy to Interrogate Cell Membrane Turnover, Neuronal Integrity, and Glial Reactions
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: Data not collected
Primary
Tensor Fractional Anisotropy Before, During, and After Chemoradiotherapy
Fractional anisotropy (FA) is a measure of the directionality of the molecular motion of water.
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: Data not collected
Primary
Vessel Diameter as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy
Time frame: Baseline, weekly during treatment, monthly following treatment for up to six months
Population: Data not collected